[
  {
    "item_id": "press_corporate__nanexa_20260203_6f822c",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products",
    "content": "10 December, 2025Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based productsThe agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales.READ MORE",
    "url": "https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:35.835725",
    "language": "en",
    "content_hash": "sha256:d9b83fe6cb94dcaa8e1245f54fd2e589b6cf48151c4b60378d8012a5e5a20125",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 61
    },
    "normalized_at": "2026-02-03T12:47:36.543775Z",
    "effective_date": "2025-12-10",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-12-10",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Nanexa and Moderna have entered into a license and option agreement for the development of up to five undisclosed compounds using Nanexa's PharmaShell® technology. Nanexa will receive an upfront payment of $3 million and is eligible for up to $500 million in potential milestone payments and royalties.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [
          "PharmaShell®"
        ],
        "indications": []
      },
      "event_classification": {
        "primary_type": "partnership",
        "confidence": 0.8
      },
      "extracted_date": "2025-12-10",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 80,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [
          "technology_family: PharmaShell"
        ],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 60,
        "entity_boosts": {
          "technology_family": 10,
          "trademark_mention": 20
        },
        "recency_boost": 10,
        "confidence_penalty": 0,
        "total": 80
      },
      "reasoning": "PharmaShell® technology mentioned, which is a medium signal for LAI. Recent partnership event date. High confidence LAI match."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 8,
      "bonuses": {
        "partnership_event": 3.0
      },
      "penalties": {},
      "final_score": 3.3,
      "effective_date": "2025-12-10",
      "score_breakdown": {
        "base_score": 8,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.82,
        "weighted_base": 0.33,
        "total_bonus": 3.0,
        "total_penalty": 0,
        "raw_score": 3.33,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20260203_516562",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults",
    "content": "Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in AdultsDecember 9, 2025December 9, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:27.028860",
    "language": "en",
    "content_hash": "sha256:c2ed94aa0c2dfe5546577b2452e9dc35255e76491c079fb1906d579722fa5fd2",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 33
    },
    "normalized_at": "2026-02-03T12:46:25.901703Z",
    "effective_date": "2025-12-09",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-12-09",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Teva Pharmaceuticals announced the submission of a New Drug Application to the U.S. FDA for an olanzapine extended-release injectable suspension (TEV-'749 / mdc-TJK) developed in partnership with Medincell for the once-monthly treatment of schizophrenia in adults.",
      "entities": {
        "companies": [],
        "molecules": [
          "olanzapine"
        ],
        "technologies": [],
        "trademarks": [
          "TEV-'749",
          "mdc-TJK"
        ],
        "indications": [
          "schizophrenia"
        ]
      },
      "event_classification": {
        "primary_type": "regulatory",
        "confidence": 0.8
      },
      "extracted_date": "2025-12-09",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 90,
      "confidence": "high",
      "signals_detected": {
        "strong": [
          "trademark: TEV-'749",
          "trademark: mdc-TJK"
        ],
        "medium": [
          "dosing_interval: once-monthly",
          "hybrid_company: Teva"
        ],
        "weak": [
          "molecule: olanzapine"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 70,
        "entity_boosts": {
          "dosing_interval": 15,
          "hybrid_company": 0,
          "trademark_mention": 20
        },
        "recency_boost": 0,
        "confidence_penalty": 0,
        "total": 90
      },
      "reasoning": "Regulatory submission for a once-monthly injectable from Teva containing trademarks TEV-'749 and mdc-TJK. Strong LAI signals with dosing interval and hybrid company mention."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 7,
      "bonuses": {
        "regulatory_event": 2.5
      },
      "penalties": {},
      "final_score": 2.8,
      "effective_date": "2025-12-09",
      "score_breakdown": {
        "base_score": 7,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.82,
        "weighted_base": 0.29,
        "total_bonus": 2.5,
        "total_penalty": 0,
        "raw_score": 2.79,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__camurus_20260203_1e8bef",
    "source_key": "press_corporate__camurus",
    "source_type": "press_corporate",
    "title": "09 January 2026RegulatoryCamurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly",
    "content": "202609 January 2026RegulatoryCamurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly202530 December 2025RegulatoryChange in number of shares and votes in Camurus16 December 2025Camurus and Gubra enter into a collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism28 November 2025RegulatoryChange in number of shares and votes in Camurus13 November 2025RegulatoryCamurus’ Nomination Committee appointed for the Annual Gene",
    "url": "https://www.camurus.com/media/press-releases/2026/camurus-announces-fda-acceptance-of-nda-resubmission-for-oclaiz-for-the-treatment-of-acromegaly/",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:39.391098",
    "language": "en",
    "content_hash": "sha256:f8e7b48eaf463948ffc29e9644ba84039abc68b77b343066cf28caad398323e4",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 63
    },
    "normalized_at": "2026-02-03T12:48:08.980499Z",
    "effective_date": "2026-01-09",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2026-01-09",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Camurus announced that the FDA has accepted the resubmission of the New Drug Application (NDA) for Oclaiz™, a long-acting treatment for acromegaly.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [
          "Oclaiz™"
        ],
        "indications": [
          "acromegaly"
        ]
      },
      "event_classification": {
        "primary_type": "regulatory",
        "confidence": 0.8
      },
      "extracted_date": "2026-01-09",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 85,
      "confidence": "high",
      "signals_detected": {
        "strong": [
          "trademark_mention: Oclaiz™"
        ],
        "medium": [
          "dosing_intervals: {{item_dosing_intervals}}"
        ],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 70,
        "entity_boosts": {
          "trademark_mention": 20
        },
        "recency_boost": 10,
        "confidence_penalty": 0,
        "total": 85
      },
      "reasoning": "Trademark Oclaiz™ mentioned along with regulatory event for acromegaly treatment. Recent date within 7 days. High confidence LAI match based on trademark and regulatory milestone."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 7,
      "bonuses": {
        "regulatory_event": 2.5
      },
      "penalties": {},
      "final_score": 2.8,
      "effective_date": "2026-01-09",
      "score_breakdown": {
        "base_score": 7,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.88,
        "weighted_base": 0.31,
        "total_bonus": 2.5,
        "total_penalty": 0,
        "raw_score": 2.81,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20260203_c147c4",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025",
    "content": "UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025November 5, 2025November 5, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/PR_MDC_Teva-earnings-Q3_2025_05112025_vf.pdf",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:27.028860",
    "language": "en",
    "content_hash": "sha256:7f3a6a00314b234fd43355bd5206916bed56d46d3f812a774fb1cbb61c28ec28",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 22
    },
    "normalized_at": "2026-02-03T12:46:47.479742Z",
    "effective_date": "2025-11-05",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-11-05",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "UZEDY® continues strong growth. Teva is preparing for a US NDA submission for Olanzapine LAI in Q4 2025.",
      "entities": {
        "companies": [],
        "molecules": [
          "Olanzapine"
        ],
        "technologies": [],
        "trademarks": [
          "UZEDY®"
        ],
        "indications": []
      },
      "event_classification": {
        "primary_type": "regulatory",
        "confidence": 0.8
      },
      "extracted_date": "2025-11-05",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 90,
      "confidence": "high",
      "signals_detected": {
        "strong": [
          "trademark: UZEDY®"
        ],
        "medium": [
          "hybrid_company: Teva",
          "dosing_interval: Q4 2025"
        ],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 70,
        "entity_boosts": {
          "hybrid_company": 0,
          "trademark": 20
        },
        "recency_boost": 0,
        "confidence_penalty": 0,
        "total": 90
      },
      "reasoning": "Teva's trademark UZEDY® mentioned along with regulatory filing timeline for an olanzapine LAI product in Q4 2025. High confidence regulatory event relevant to LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 7,
      "bonuses": {
        "regulatory_event": 2.5
      },
      "penalties": {
        "aging_penalty": -0.5
      },
      "final_score": 2.3,
      "effective_date": "2025-11-05",
      "score_breakdown": {
        "base_score": 7,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.75,
        "weighted_base": 0.26,
        "total_bonus": 2.5,
        "total_penalty": -0.5,
        "raw_score": 2.26,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20260203_4ce385",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation",
    "content": "PRESSRELEASES27 January, 2026Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide FormulationNanexa’s atomic layer deposition (ALD) platform PharmaShell® demonstrably improves the pharmacokinetic profile of semaglutide injections.Significantly smoother plasma concentration curve could mitigate many common side effects of GLP-1 drugs.Read moreREAD MORE10 December, 2025Nanexa and Moderna enter into license and option agreement for",
    "url": "https://nanexa.com/mfn_news/nanexa-announces-breakthrough-preclinical-data-demonstrating-exceptional-pharmacokinetic-profile-for-monthly-semaglutide-formulation/",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:35.835725",
    "language": "en",
    "content_hash": "sha256:afea17df7bd4fa6526d533e909def01570a7b73dbc6cf35af9ab3980f53efc10",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 55
    },
    "normalized_at": "2026-02-03T12:47:23.236499Z",
    "effective_date": "2026-01-27",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2026-01-27",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Nanexa announced preclinical data showing its PharmaShell® atomic layer deposition platform improved the pharmacokinetic profile of monthly semaglutide injections, potentially mitigating side effects of GLP-1 drugs.",
      "entities": {
        "companies": [],
        "molecules": [
          "semaglutide"
        ],
        "technologies": [],
        "trademarks": [
          "PharmaShell®"
        ],
        "indications": []
      },
      "event_classification": {
        "primary_type": "clinical_update",
        "confidence": 0.8
      },
      "extracted_date": "2026-01-27",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 75,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [
          "technology_family: PharmaShell",
          "dosing_interval: monthly injection"
        ],
        "weak": [
          "molecule: semaglutide"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 50,
        "entity_boosts": {
          "dosing_interval": 15,
          "technology_family": 10,
          "molecule": 0
        },
        "recency_boost": 0,
        "confidence_penalty": 0,
        "total": 75
      },
      "reasoning": "The item mentions the PharmaShell technology for enabling monthly semaglutide injections, a clear LAI signal. With a clinical update event type and recent date, this is a high confidence LAI match."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 6,
      "bonuses": {
        "clinical_event": 2.0
      },
      "penalties": {},
      "final_score": 2.3,
      "effective_date": "2026-01-27",
      "score_breakdown": {
        "base_score": 6,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.95,
        "weighted_base": 0.29,
        "total_bonus": 2.0,
        "total_penalty": 0,
        "raw_score": 2.29,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20260203_4ce385",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation",
    "content": "27 January, 2026Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide FormulationNanexa’s atomic layer deposition (ALD) platform PharmaShell® demonstrably improves the pharmacokinetic profile of semaglutide injections.Significantly smoother plasma concentration curve could mitigate many common side effects of GLP-1 drugs.Read moreREAD MORE",
    "url": "https://nanexa.com/mfn_news/nanexa-announces-breakthrough-preclinical-data-demonstrating-exceptional-pharmacokinetic-profile-for-monthly-semaglutide-formulation/",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:35.835725",
    "language": "en",
    "content_hash": "sha256:487400f57c4245d14b4bdbc629d08024146dadfef92fcb771eb0ffefe5e0401c",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 44
    },
    "normalized_at": "2026-02-03T12:47:30.439370Z",
    "effective_date": "2026-01-27",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2026-01-27",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Nanexa announced preclinical data showing its atomic layer deposition (ALD) platform PharmaShell® improves the pharmacokinetic profile of monthly semaglutide injections, potentially mitigating side effects of GLP-1 drugs.",
      "entities": {
        "companies": [],
        "molecules": [
          "semaglutide"
        ],
        "technologies": [],
        "trademarks": [
          "PharmaShell®"
        ],
        "indications": []
      },
      "event_classification": {
        "primary_type": "clinical_update",
        "confidence": 0.8
      },
      "extracted_date": "2026-01-27",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 80,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [
          "dosing_interval: monthly injection",
          "technology_family: PharmaShell®",
          "technology_family: atomic layer deposition"
        ],
        "weak": [
          "molecule: semaglutide"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 50,
        "entity_boosts": {
          "dosing_interval": 15,
          "technology_family": 10,
          "molecule": 15
        },
        "recency_boost": 10,
        "confidence_penalty": 0,
        "total": 80
      },
      "reasoning": "The item mentions a monthly semaglutide injection formulated using the PharmaShell® atomic layer deposition technology, which are clear signals for a long-acting injectable. The recent date and clinical update event type further support high relevance."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 6,
      "bonuses": {
        "clinical_event": 2.0
      },
      "penalties": {},
      "final_score": 2.3,
      "effective_date": "2026-01-27",
      "score_breakdown": {
        "base_score": 6,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.95,
        "weighted_base": 0.29,
        "total_bonus": 2.0,
        "total_penalty": 0,
        "raw_score": 2.29,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__fiercebiotech_20260203_8f7e97",
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/novos-cagrisema-tops-semaglutide-ph-3-diabetes-study-still-falls-short-25-weight-loss-goal\" hreflang=\"en\">Novo’s CagriSema tops semaglutide in ph. 3 diabetes study</a>",
    "content": "Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema still didn't hit the 25% weight loss mark that the Danish pharma had previously laid out for its next-gen metabolic asset.",
    "url": "https://www.fiercebiotech.com/biotech/novos-cagrisema-tops-semaglutide-ph-3-diabetes-study-still-falls-short-25-weight-loss-goal",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:38.109109",
    "language": "en",
    "content_hash": "sha256:62e100bc2ae918bad3ab843193e112fa727f5ecdc095f45014a7c26b7c928ae2",
    "metadata": {
      "author": "Darren Incorvaia",
      "tags": [],
      "word_count": 39
    },
    "normalized_at": "2026-02-03T12:47:57.010939Z",
    "effective_date": "2026-02-03",
    "date_metadata": {
      "source": "published_at",
      "bedrock_date": null,
      "bedrock_confidence": 0.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Novo Nordisk's GLP-1/amylin combo CagriSema outperformed semaglutide in a phase 3 trial for Type 2 diabetes, but did not achieve the 25% weight loss goal set by the company.",
      "entities": {
        "companies": [],
        "molecules": [
          "CagriSema",
          "semaglutide"
        ],
        "technologies": [],
        "trademarks": [],
        "indications": [
          "Type 2 diabetes"
        ]
      },
      "event_classification": {
        "primary_type": "clinical_update",
        "confidence": 0.8
      },
      "extracted_date": null,
      "date_confidence": 0.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 80,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [
          "technology_family: microspheres",
          "dosing_interval: once-weekly",
          "hybrid_company: Novo Nordisk"
        ],
        "weak": [
          "molecule: semaglutide"
        ],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 50,
        "entity_boosts": {
          "dosing_interval": 15,
          "hybrid_company": 10,
          "technology_family": 10
        },
        "recency_boost": 5,
        "confidence_penalty": 0,
        "total": 80
      },
      "reasoning": "Microsphere technology, weekly dosing interval, and hybrid company Novo Nordisk mentioned. Clinical update event type with recent date. High confidence LAI match."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 6,
      "bonuses": {
        "clinical_event": 2.0
      },
      "penalties": {},
      "final_score": 2.3,
      "effective_date": "2026-02-03",
      "score_breakdown": {
        "base_score": 6,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.3,
        "total_bonus": 2.0,
        "total_penalty": 0,
        "raw_score": 2.3,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__fiercebiotech_20260203_8d1e08",
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/wave-regains-rights-genetic-disease-rna-editor-gsk\" hreflang=\"en\">GSK gives back rights to Wave's genetic disease RNA editor</a>",
    "content": "Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. GSK has decided not to take over development of WVE-006, an experimental oligonucleotide for alpha-1 antitrypsin deficiency (AATD), with Massachusetts-based Wave reclaiming full rights and planning to seek accelerated approval for the asset from the FDA.",
    "url": "https://www.fiercebiotech.com/biotech/wave-regains-rights-genetic-disease-rna-editor-gsk",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:38.109109",
    "language": "en",
    "content_hash": "sha256:05cdfb808f57707b6c5d79a02f2433a7a7f256f5e155879ffb63848f83d8a49c",
    "metadata": {
      "author": "Darren Incorvaia",
      "tags": [],
      "word_count": 53
    },
    "normalized_at": "2026-02-03T12:48:02.953634Z",
    "effective_date": "2023-05-18",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2023-05-18",
      "bedrock_confidence": 0.9,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Wave Life Sciences has regained full rights to its lead RNA editing candidate WVE-006 for alpha-1 antitrypsin deficiency (AATD) from GSK. Wave plans to seek accelerated approval for WVE-006 from the FDA.",
      "entities": {
        "companies": [],
        "molecules": [
          "WVE-006"
        ],
        "technologies": [],
        "trademarks": [],
        "indications": [
          "alpha-1 antitrypsin deficiency (AATD)"
        ]
      },
      "event_classification": {
        "primary_type": "partnership",
        "confidence": 0.8
      },
      "extracted_date": "2023-05-18",
      "date_confidence": 0.9,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 80,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [
          "technology_family: RNA editing"
        ],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 60,
        "entity_boosts": {
          "technology_family": 10,
          "molecule": 15
        },
        "recency_boost": 5,
        "confidence_penalty": 0,
        "total": 80
      },
      "reasoning": "RNA editing technology and molecule WVE-006 detected. Partnership event with recent date. High confidence LAI match due to novel RNA editing platform technology."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 8,
      "bonuses": {
        "partnership_event": 3.0
      },
      "penalties": {
        "very_old_penalty": -2.0
      },
      "final_score": 1.2,
      "effective_date": "2023-05-18",
      "score_breakdown": {
        "base_score": 8,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.2,
        "total_bonus": 3.0,
        "total_penalty": -2.0,
        "raw_score": 1.2,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__endpoints_news_20260130_e5a715",
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "FDA says it explained issues early on for Corcept's rejected Cushing's syndrome drug",
    "content": "An FDA rejection letter for Corcept Therapeutics’ potential hormonal disorder drug says the agency told the company it had serious concerns before the application was submitted.\n\n The complete response letter, released ...",
    "url": "https://endpoints.news/fda-says-it-explained-issues-early-on-for-corcepts-rejected-cushings-syndrome-drug/",
    "published_at": "2026-01-30",
    "ingested_at": "2026-02-03T09:48:29.915620",
    "language": "en",
    "content_hash": "sha256:6cdac381b8a5565cbdd95bc9b14a0c0a2b1709c0cace218a238993b1a3a81000",
    "metadata": {
      "author": "Zachary Brennan",
      "tags": [
        "Pharma",
        "FDA+"
      ],
      "word_count": 32
    },
    "normalized_at": "2026-02-03T12:46:59.403432Z",
    "effective_date": "2026-01-30",
    "date_metadata": {
      "source": "published_at",
      "bedrock_date": "2023-05-24",
      "bedrock_confidence": 0.0,
      "published_at": "2026-01-30"
    },
    "normalized_content": {
      "summary": "The FDA rejected Corcept Therapeutics' application for a potential hormonal disorder drug, stating that it had raised serious concerns with the company before the application was submitted.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [
          "Cushing's syndrome"
        ]
      },
      "event_classification": {
        "primary_type": "regulatory",
        "confidence": 0.8
      },
      "extracted_date": "2023-05-24",
      "date_confidence": 0.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No LAI signals detected in the item. The item is about a regulatory rejection for a drug to treat Cushing's syndrome, with no mention of long-acting injectable technologies or formulations."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 7,
      "bonuses": {
        "regulatory_event": 2.5
      },
      "penalties": {
        "no_entities_penalty": -2.0
      },
      "final_score": 0.8,
      "effective_date": "2026-01-30",
      "score_breakdown": {
        "base_score": 7,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.95,
        "weighted_base": 0.33,
        "total_bonus": 2.5,
        "total_penalty": -2.0,
        "raw_score": 0.83,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__endpoints_news_20260130_555425",
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Quince's steroid therapy for rare disease fails, shares tank",
    "content": "Quince Therapeutics' once-monthly steroid-based treatment failed a Phase 3 trial for a rare genetic condition called ataxia-telangiectasia, prompting the Bay Area company to say it would stop development of the experimental ...",
    "url": "https://endpoints.news/quinces-steroid-therapy-for-rare-disease-fails-shares-tank/",
    "published_at": "2026-01-30",
    "ingested_at": "2026-02-03T09:48:29.915620",
    "language": "en",
    "content_hash": "sha256:fce9b8a0bd264083183518878c872a1fb8a64ae753c4cbecab9532bca59a5eab",
    "metadata": {
      "author": "Lei Lei Wu",
      "tags": [
        "R&D"
      ],
      "word_count": 32
    },
    "normalized_at": "2026-02-03T12:47:04.448694Z",
    "effective_date": "2026-01-30",
    "date_metadata": {
      "source": "published_at",
      "bedrock_date": null,
      "bedrock_confidence": 0.0,
      "published_at": "2026-01-30"
    },
    "normalized_content": {
      "summary": "Quince Therapeutics' once-monthly steroid-based treatment failed a Phase 3 trial for the rare genetic condition ataxia-telangiectasia. The company said it would stop development of the experimental therapy.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [
          "ataxia-telangiectasia"
        ]
      },
      "event_classification": {
        "primary_type": "clinical_update",
        "confidence": 0.8
      },
      "extracted_date": null,
      "date_confidence": 0.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No LAI signals detected. The item is about a failed clinical trial for a steroid therapy for a rare disease, with no mention of long-acting injectable technologies or formulations."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 6,
      "bonuses": {
        "clinical_event": 2.0
      },
      "penalties": {
        "no_entities_penalty": -2.0
      },
      "final_score": 0.3,
      "effective_date": "2026-01-30",
      "score_breakdown": {
        "base_score": 6,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.95,
        "weighted_base": 0.29,
        "total_bonus": 2.0,
        "total_penalty": -2.0,
        "raw_score": 0.29,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__delsitech_20260203_e3d7ad",
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Partnership Opportunities in Drug Delivery 2025 Boston, October 27-28",
    "content": "Partnership Opportunities in Drug Delivery 2025 Boston, October 27-28Essi Nevo2025-08-15T11:33:54+02:00August 15th, 2025|Read More",
    "url": "https://www.delsitech.com/partnership-opportunities-in-drug-delivery-2025-boston-october-27-28/",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:41.015379",
    "language": "en",
    "content_hash": "sha256:9362998c5af4ef533152f4c2d2f7f2a5a831f17fb5c84d2e9918492eabf312d7",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 13
    },
    "normalized_at": "2026-02-03T12:48:13.877183Z",
    "effective_date": "2025-08-15",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-08-15",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "The news item is about a conference titled 'Partnership Opportunities in Drug Delivery 2025' taking place in Boston on October 27-28.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "partnership",
        "confidence": 0.8
      },
      "extracted_date": "2025-08-15",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No LAI signals detected. The item is about a conference on partnership opportunities in drug delivery, with no specific mention of long-acting injectables or related technologies."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 8,
      "bonuses": {
        "partnership_event": 3.0
      },
      "penalties": {
        "old_penalty": -1.0,
        "no_entities_penalty": -2.0
      },
      "final_score": 0.3,
      "effective_date": "2025-08-15",
      "score_breakdown": {
        "base_score": 8,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.65,
        "weighted_base": 0.26,
        "total_bonus": 3.0,
        "total_penalty": -3.0,
        "raw_score": 0.26,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__endpoints_news_20260130_3ccb5e",
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Lilly unveils $3.5B factory that will make retatrutide and other obesity drugs",
    "content": "Eli Lilly has budgeted $3.5 billion for a new weight loss injectable and device factory in Lehigh Valley, PA, which will manufacture its next-gen obesity drug retatrutide.\n\n The factory will also produce other weight loss ...",
    "url": "https://endpoints.news/lilly-unveils-3-5b-factory-that-will-make-retatrutide-and-other-obesity-drugs/",
    "published_at": "2026-01-30",
    "ingested_at": "2026-02-03T09:48:29.915620",
    "language": "en",
    "content_hash": "sha256:9b5fe1755f1f18826c1f8226bbeb1e15111f9d110a587878e4157133b3ef8fa8",
    "metadata": {
      "author": "Anna Brown",
      "tags": [
        "Pharma",
        "Manufacturing"
      ],
      "word_count": 36
    },
    "normalized_at": "2026-02-03T12:47:10.461375Z",
    "effective_date": "2026-01-30",
    "date_metadata": {
      "source": "published_at",
      "bedrock_date": null,
      "bedrock_confidence": 0.0,
      "published_at": "2026-01-30"
    },
    "normalized_content": {
      "summary": "Eli Lilly has budgeted $3.5 billion for a new factory in Lehigh Valley, PA that will manufacture its next-generation obesity drug retatrutide and other weight loss injectables.",
      "entities": {
        "companies": [],
        "molecules": [
          "retatrutide"
        ],
        "technologies": [],
        "trademarks": [],
        "indications": [
          "obesity"
        ]
      },
      "event_classification": {
        "primary_type": "corporate_move",
        "confidence": 0.8
      },
      "extracted_date": null,
      "date_confidence": 0.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 65,
      "confidence": "medium",
      "signals_detected": {
        "strong": [],
        "medium": [
          "technology_family: microspheres",
          "dosing_interval: obesity"
        ],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 40,
        "entity_boosts": {
          "technology_family": 10,
          "dosing_interval": 15
        },
        "recency_boost": 0,
        "confidence_penalty": 0,
        "total": 65
      },
      "reasoning": "The item mentions microspheres technology and the obesity indication, which is a dosing interval signal for LAIs. Corporate move event type. Medium confidence LAI match."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 5.0,
      "bonuses": {},
      "penalties": {},
      "final_score": 0.2,
      "effective_date": "2026-01-30",
      "score_breakdown": {
        "base_score": 5.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.95,
        "weighted_base": 0.24,
        "total_bonus": 0,
        "total_penalty": 0,
        "raw_score": 0.24,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20260203_aa5561",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) ; OLANZAPINE LAI: EU Submission Expected in Q2 2026",
    "content": "UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) ; OLANZAPINE LAI: EU Submission Expected in Q2 2026January 28, 2026January 28, 2026",
    "url": "https://www.medincell.com/wp-content/uploads/2026/01/PR_MDC_TevaQ42025results_EN_28012026_vf.pdf",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:27.028860",
    "language": "en",
    "content_hash": "sha256:58323a1cdefb125396e7beaff04ca98f6f11f926a9ad5fe5eac3cf61347873a8",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 26
    },
    "normalized_at": "2026-02-03T12:46:08.842517Z",
    "effective_date": "2026-01-28",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2026-01-28",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "UZEDY® net sales increased from $117M in 2024 to $191M in 2025, a 63% increase. An EU submission for OLANZAPINE LAI is expected in Q2 2026.",
      "entities": {
        "companies": [],
        "molecules": [
          "OLANZAPINE"
        ],
        "technologies": [],
        "trademarks": [
          "UZEDY®"
        ],
        "indications": []
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "extracted_date": "2026-01-28",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 85,
      "confidence": "high",
      "signals_detected": {
        "strong": [
          "trademark: UZEDY®"
        ],
        "medium": [
          "dosing_interval: quarterly injection",
          "hybrid_company: Johnson & Johnson"
        ],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 0,
        "entity_boosts": {
          "trademark_mention": 20,
          "dosing_interval": 15,
          "hybrid_company": 10
        },
        "recency_boost": 10,
        "confidence_penalty": 0,
        "total": 85
      },
      "reasoning": "UZEDY® is a trademark for a long-acting injectable product. Quarterly dosing interval and Johnson & Johnson (hybrid company) mentioned. Recent financial results with LAI context. High confidence match."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2026-01-28",
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.95,
        "weighted_base": 0.14,
        "total_bonus": 0,
        "total_penalty": -1.0,
        "raw_score": -0.86,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20260203_662f02",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Publication of the 2026 financial calendar",
    "content": "Publication of the 2026 financial calendarJanuary 12, 2026January 12, 2026",
    "url": "https://www.medincell.com/wp-content/uploads/2026/01/MDC_Agenda2026_12012026_EN_vf.pdf",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:27.028860",
    "language": "en",
    "content_hash": "sha256:87aae11e6edc5e0ffed9cc27be20b0ce9a948ff6861602998c7fe882321e4026",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 10
    },
    "normalized_at": "2026-02-03T12:46:13.327470Z",
    "effective_date": "2026-01-12",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2026-01-12",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "The news item announces the publication of the 2026 financial calendar. No other details are provided.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "extracted_date": "2026-01-12",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No LAI signals detected. Financial results announcement with no explicit LAI content. Rejected per rule_5."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2026-01-12",
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.88,
        "weighted_base": 0.13,
        "total_bonus": 0,
        "total_penalty": -3.0,
        "raw_score": -2.87,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20260203_2b08cd",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)",
    "content": "Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)December 9, 2025December 9, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_HY-Results-EN_09122025-1.pdf",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:27.028860",
    "language": "en",
    "content_hash": "sha256:d31f0b2539d43d16674e54130adf76dadd16de4d64da01b46089ef7d05087f56",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 19
    },
    "normalized_at": "2026-02-03T12:46:18.411753Z",
    "effective_date": "2025-12-09",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-12-09",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Medincell published its consolidated financial results for the half-year period from April 1st, 2025 to September 30, 2025.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "extracted_date": "2025-12-09",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "The item is about financial results with no explicit mention of LAI technologies, products or companies. Per rule_5, financial results need at least 2 LAI signals to be considered relevant, which is not the case here."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2025-12-09",
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.82,
        "weighted_base": 0.12,
        "total_bonus": 0,
        "total_penalty": -3.0,
        "raw_score": -2.88,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20260203_150759",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Awarded New Grant to Fight Malaria",
    "content": "Medincell Awarded New Grant to Fight MalariaNovember 24, 2025November 24, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_Gates-Malaria_PR_24112025_vf.pdf",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:27.028860",
    "language": "en",
    "content_hash": "sha256:2077438074167cf84530cd63f435d4d32c7966446ec74b1d2d88da3c63b8e447",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 11
    },
    "normalized_at": "2026-02-03T12:46:31.727567Z",
    "effective_date": "2025-11-24",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-11-24",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Medincell was awarded a new grant to fight malaria. The news article does not mention any specific long-acting injectable (LAI) technologies or dosing intervals.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [
          "malaria"
        ]
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "extracted_date": "2025-11-24",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "The item mentions Medincell being awarded a grant to fight malaria, but does not provide any details about long-acting injectable technologies or dosing intervals. Based on the matching rules, a financial results event requires at least 2 medium or strong signals to be considered LAI-relevant, which are not present here. Therefore, this item is not relevant to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "aging_penalty": -0.5,
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2025-11-24",
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.75,
        "weighted_base": 0.11,
        "total_bonus": 0,
        "total_penalty": -3.5,
        "raw_score": -3.39,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20260203_63c5d2",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth",
    "content": "Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital GrowthNovember 11, 2025November 11, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_G_KIM_10112025_EN_vf.pdf",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:27.028860",
    "language": "en",
    "content_hash": "sha256:0fd65830bac79a1367fb57ebdb608040c3d60da28c61faceaa909e7a158b29f2",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 23
    },
    "normalized_at": "2026-02-03T12:46:36.573961Z",
    "effective_date": "2025-11-11",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-11-11",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Medincell, a biotech company, appointed Dr. Grace Kim as Chief Strategy Officer for U.S. Finance to advance the company's growth in the U.S. capital market.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "corporate_move",
        "confidence": 0.8
      },
      "extracted_date": "2025-11-11",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No LAI signals detected. The item is about a corporate appointment and does not mention any LAI technologies or products."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 5.0,
      "bonuses": {},
      "penalties": {
        "aging_penalty": -0.5,
        "no_entities_penalty": -2.0
      },
      "final_score": 0,
      "effective_date": "2025-11-11",
      "score_breakdown": {
        "base_score": 5.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.75,
        "weighted_base": 0.19,
        "total_bonus": 0,
        "total_penalty": -2.5,
        "raw_score": -2.31,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__medincell_20260203_846e38",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark",
    "content": "Medincell to Join MSCI World Small Cap Index, a Leading Global BenchmarkNovember 10, 2025November 10, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_MSCI-Small-Index_10112025_EN_vf.pdf",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:27.028860",
    "language": "en",
    "content_hash": "sha256:56a3453e4ee40153ae56677367b25aa29f62e6fdeeba03e4c9c8d2f2706a1923",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 16
    },
    "normalized_at": "2026-02-03T12:46:41.317785Z",
    "effective_date": "2025-11-10",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-11-10",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Medincell, a pharmaceutical company, will be added to the MSCI World Small Cap Index, a leading global benchmark index.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "corporate_move",
        "confidence": 0.8
      },
      "extracted_date": "2025-11-10",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No LAI signals detected. Item is about a company being added to a stock index, which is not relevant to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 5.0,
      "bonuses": {},
      "penalties": {
        "aging_penalty": -0.5,
        "no_entities_penalty": -2.0
      },
      "final_score": 0,
      "effective_date": "2025-11-10",
      "score_breakdown": {
        "base_score": 5.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.75,
        "weighted_base": 0.19,
        "total_bonus": 0,
        "total_penalty": -2.5,
        "raw_score": -2.31,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__endpoints_news_20260131_cee7af",
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Big Pharma earnings kick off; Third-round IRA drugs selected; Hengrui’s trailblazing moment; and more",
    "content": "Welcome back to Endpoints Weekly! Fourth-quarter earnings season is in full swing, and our team covered reports this week from Teva, Roche, Sanofi, Takeda and Regeneron. CMS also unveiled the next 15 drugs subject to ...",
    "url": "https://endpoints.news/big-pharma-earnings-kick-off-third-round-ira-drugs-selected-hengruis-trailblazing-moment-and-more/",
    "published_at": "2026-01-31",
    "ingested_at": "2026-02-03T09:48:29.915620",
    "language": "en",
    "content_hash": "sha256:7b31cfd308f7cdc80884c6af12fe7fd16627d14ab2f4bd761b73b531b09cb3aa",
    "metadata": {
      "author": "Max Gelman",
      "tags": [
        "Weekly"
      ],
      "word_count": 36
    },
    "normalized_at": "2026-02-03T12:46:53.368149Z",
    "effective_date": "2023-01-27",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2023-01-27",
      "bedrock_confidence": 0.8,
      "published_at": "2026-01-31"
    },
    "normalized_content": {
      "summary": "The article discusses fourth-quarter earnings reports from major pharmaceutical companies like Teva, Roche, Sanofi, Takeda, and Regeneron. It also mentions that CMS unveiled the next 15 drugs subject to price negotiations under the Inflation Reduction Act.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "extracted_date": "2023-01-27",
      "date_confidence": 0.8,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "The item discusses financial results from major pharmaceutical companies and the selection of drugs for price negotiations under the Inflation Reduction Act. No LAI-specific signals were detected, and the event type 'financial_results' requires explicit LAI content to be considered relevant according to the matching rules."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "very_old_penalty": -2.0,
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2023-01-27",
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.08,
        "total_bonus": 0,
        "total_penalty": -5.0,
        "raw_score": -4.92,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__endpoints_news_20260130_4f53a1",
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "AstraZeneca pays $1.2B for CSPC's long-acting obesity drugs",
    "content": "AstraZeneca is already delivering on its $15 billion commitment to China with a $1.2 billion upfront pact with CSPC Pharmaceutical, spanning eight drug programs and multiple platform technologies.\n\n On Thursday, the UK ...",
    "url": "https://endpoints.news/astrazeneca-pays-1-2b-for-cspcs-long-acting-obesity-drugs/",
    "published_at": "2026-01-30",
    "ingested_at": "2026-02-03T09:48:29.915620",
    "language": "en",
    "content_hash": "sha256:fc75e15cf7c086510c30536ce3edbc882df288a665a9ea3f04532458fef770c5",
    "metadata": {
      "author": "Kyle LaHucik",
      "tags": [
        "Deals",
        "China"
      ],
      "word_count": 33
    },
    "normalized_at": "2026-02-03T12:47:16.350124Z",
    "effective_date": "2023-05-18",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2023-05-18",
      "bedrock_confidence": 0.8,
      "published_at": "2026-01-30"
    },
    "normalized_content": {
      "summary": "AstraZeneca has entered into a $1.2 billion upfront partnership with CSPC Pharmaceutical spanning eight drug programs and multiple platform technologies for long-acting obesity drugs.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": [
          "obesity"
        ]
      },
      "event_classification": {
        "primary_type": "partnership",
        "confidence": 0.8
      },
      "extracted_date": "2023-05-18",
      "date_confidence": 0.8,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 85,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [
          "dosing_intervals: long-acting obesity drugs",
          "technology_families: long-acting"
        ],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 60,
        "entity_boosts": {
          "dosing_interval": 15,
          "technology_family": 10
        },
        "recency_boost": 0,
        "confidence_penalty": 0,
        "total": 85
      },
      "reasoning": "Partnership involving long-acting obesity drugs and long-acting technologies. High confidence LAI match based on multiple medium signals."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 8,
      "bonuses": {
        "partnership_event": 3.0
      },
      "penalties": {
        "very_old_penalty": -2.0,
        "no_entities_penalty": -2.0
      },
      "final_score": 0,
      "effective_date": "2023-05-18",
      "score_breakdown": {
        "base_score": 8,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.2,
        "total_bonus": 3.0,
        "total_penalty": -4.0,
        "raw_score": -0.8,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20260203_ec88d7",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "content": "6 November, 2025Nanexa publishes interim report for January-September 2025Download attachment",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:35.835725",
    "language": "en",
    "content_hash": "sha256:5e92a34fa02feb0c756160060d140bd43be564d228173af1a7475fc55abd2012",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 10
    },
    "normalized_at": "2026-02-03T12:47:41.838137Z",
    "effective_date": "2025-11-06",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-11-06",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Nanexa, a pharmaceutical company, published its interim financial report for the period of January to September 2025.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "extracted_date": "2025-11-06",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "The item is about financial results with no mention of LAI technologies, companies, molecules or dosing intervals. Rule 5 triggered: 'reject (financial results need explicit LAI content)' since signals_count < 2."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "aging_penalty": -0.5,
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2025-11-06",
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.75,
        "weighted_base": 0.11,
        "total_bonus": 0,
        "total_penalty": -3.5,
        "raw_score": -3.39,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20260203_e8d104",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Download attachment",
    "content": "Download attachment",
    "url": "https://storage.mfn.se/ab91ff14-4c8b-4c40-85a9-996052a19950/nanexa-interim-report-january-september-2025.pdf",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:35.835725",
    "language": "en",
    "content_hash": "sha256:3d03c0ba4af110790f2466800ad3cb177d90875ff5aca390550800cb8fb5b287",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 2
    },
    "normalized_at": "2026-02-03T12:47:45.982959Z",
    "effective_date": "2026-02-03",
    "date_metadata": {
      "source": "published_at",
      "bedrock_date": null,
      "bedrock_confidence": 0.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "No factual summary can be provided as the given text does not contain any relevant content.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "other",
        "confidence": 0.8
      },
      "extracted_date": null,
      "date_confidence": 0.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No relevant signals or exclusions detected. The given text does not contain any content related to long-acting injectables."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 2.0,
      "bonuses": {},
      "penalties": {
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2026-02-03",
      "score_breakdown": {
        "base_score": 2.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.1,
        "total_bonus": 0,
        "total_penalty": -3.0,
        "raw_score": -2.9,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__nanexa_20260203_76ad60",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-June 2025",
    "content": "27 August, 2025Nanexa publishes interim report for January-June 2025Download attachment",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-june-2025/",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:35.835725",
    "language": "en",
    "content_hash": "sha256:5ebaa7e082a1cf6d1df5f67bacd000c99e99c281c9cc7c0d2499114067d696b3",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 10
    },
    "normalized_at": "2026-02-03T12:47:50.683112Z",
    "effective_date": "2025-08-27",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-08-27",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Nanexa, a pharmaceutical company, published its interim financial report for the first half of 2025.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "financial_results",
        "confidence": 0.8
      },
      "extracted_date": "2025-08-27",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "Financial results with no LAI-specific signals detected. Rule rule_5 triggered: reject (financial results need explicit LAI content)."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 3.0,
      "bonuses": {},
      "penalties": {
        "old_penalty": -1.0,
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2025-08-27",
      "score_breakdown": {
        "base_score": 3.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.65,
        "weighted_base": 0.1,
        "total_bonus": 0,
        "total_penalty": -4.0,
        "raw_score": -3.9,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__delsitech_20260203_ad0afc",
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "BIO International Convention 2025 Boston, June 16-19",
    "content": "BIO International Convention 2025 Boston, June 16-19Aleksi Leino2025-06-12T15:59:56+02:00June 12th, 2025|Read More",
    "url": "https://www.delsitech.com/bio-international-convention-2025-boston-june-16-19/",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:41.015379",
    "language": "en",
    "content_hash": "sha256:57720ff336bac6a3ca5237373c94baaa3eec122461772429e7c57553296abdcf",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 11
    },
    "normalized_at": "2026-02-03T12:48:18.330191Z",
    "effective_date": "2025-06-12",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-06-12",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "The BIO International Convention 2025 will be held in Boston from June 16-19, 2025.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "other",
        "confidence": 0.8
      },
      "extracted_date": "2025-06-12",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No LAI signals detected. Item is about a general biotech convention, not specific to long-acting injectables."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 2.0,
      "bonuses": {},
      "penalties": {
        "very_old_penalty": -2.0,
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2025-06-12",
      "score_breakdown": {
        "base_score": 2.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.05,
        "total_bonus": 0,
        "total_penalty": -5.0,
        "raw_score": -4.95,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__delsitech_20260203_dddc9f",
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Bio Europe Spring 2025 Milan, March 17-19",
    "content": "Bio Europe Spring 2025 Milan, March 17-19Milla Runsala2025-02-19T12:33:49+02:00February 17th, 2025|Read More",
    "url": "https://www.delsitech.com/bio-europe-spring-2025-milan-march-17-19/",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:41.015379",
    "language": "en",
    "content_hash": "sha256:960cdcae688eed2f19c4753685af51b62ae13017e3fbf4bbac02a4822228face",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 11
    },
    "normalized_at": "2026-02-03T12:48:22.795048Z",
    "effective_date": "2025-02-19",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-02-19",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Bio Europe Spring 2025 is an event taking place in Milan from March 17-19, 2025.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "other",
        "confidence": 0.8
      },
      "extracted_date": "2025-02-19",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No LAI signals detected. Item is about a general biotech event with no specific LAI relevance."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 2.0,
      "bonuses": {},
      "penalties": {
        "very_old_penalty": -2.0,
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2025-02-19",
      "score_breakdown": {
        "base_score": 2.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.05,
        "total_bonus": 0,
        "total_penalty": -5.0,
        "raw_score": -4.95,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_corporate__delsitech_20260203_e99236",
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "TIDES Asia 2025 Kyoto, February 26-28",
    "content": "TIDES Asia 2025 Kyoto, February 26-28Milla Runsala2025-02-19T12:49:02+02:00February 15th, 2025|Read More",
    "url": "https://www.delsitech.com/tides-asia-2025-kyoto-february-26-28/",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:41.015379",
    "language": "fr",
    "content_hash": "sha256:7837e99508bbf82ae906e463ce964af3d7356e0c7525d68b3b8b0fb61c71c383",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 10
    },
    "normalized_at": "2026-02-03T12:48:27.332120Z",
    "effective_date": "2025-02-19",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2025-02-19",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "TIDES Asia 2025 is an event taking place in Kyoto from February 26-28, 2025.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "other",
        "confidence": 0.8
      },
      "extracted_date": "2025-02-19",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No LAI signals detected. Item is about a general event with no relevant entities or technologies mentioned. Not LAI-relevant."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 2.0,
      "bonuses": {},
      "penalties": {
        "very_old_penalty": -2.0,
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2025-02-19",
      "score_breakdown": {
        "base_score": 2.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.05,
        "total_bonus": 0,
        "total_penalty": -5.0,
        "raw_score": -4.95,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__fiercepharma_20260203_e86749",
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/sponsored/why-human-expertise-still-matters-ai-driven-med-comms\" hreflang=\"en\">Why human expertise still matters in AI-driven med comms</a>",
    "content": "RTI Health Solutions experts explain how AI can help medical communications without replacing rigor, judgment or trust.",
    "url": "https://www.fiercepharma.com/sponsored/why-human-expertise-still-matters-ai-driven-med-comms",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:43.176623",
    "language": "en",
    "content_hash": "sha256:99a606c9ac3663f315d153a03429d770f20938f38a99a66a8792312343dc406f",
    "metadata": {
      "author": "Questex Partner",
      "tags": [],
      "word_count": 17
    },
    "normalized_at": "2026-02-03T12:48:31.932656Z",
    "effective_date": "2026-02-03",
    "date_metadata": {
      "source": "published_at",
      "bedrock_date": null,
      "bedrock_confidence": 0.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "RTI Health Solutions experts explain how AI can help medical communications without replacing rigor, judgment or trust.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "other",
        "confidence": 0.8
      },
      "extracted_date": null,
      "date_confidence": 0.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No LAI signals detected. The item is about the role of human expertise in AI-driven medical communications, which is not directly relevant to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 2.0,
      "bonuses": {},
      "penalties": {
        "no_entities_penalty": -2.0,
        "low_relevance_event": -1.0
      },
      "final_score": 0,
      "effective_date": "2026-02-03",
      "score_breakdown": {
        "base_score": 2.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 1.0,
        "weighted_base": 0.1,
        "total_bonus": 0,
        "total_penalty": -3.0,
        "raw_score": -2.9,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__fiercepharma_20260203_fc4458",
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/lilly-rounds-out-quartet-new-us-plants-35b-injectables-and-device-facility-pa\" hreflang=\"en\">Lilly rounds out quartet of new US plants with $3.5B injectable and device facility in PA</a>",
    "content": "On Friday, Eli Lilly unveiled designs on a new, $3.5 billion manufacturing facility in Pennsylvania’s Lehigh Valley, rounding out the quartet of plants it promised during its “Lilly in America” investment announcement last year.",
    "url": "https://www.fiercepharma.com/pharma/lilly-rounds-out-quartet-new-us-plants-35b-injectables-and-device-facility-pa",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:43.176623",
    "language": "en",
    "content_hash": "sha256:9d428f4881bc9150761744dfa4e1008b691f6e9e101fadef4f9a23b7041bd47f",
    "metadata": {
      "author": "Fraiser Kansteiner",
      "tags": [],
      "word_count": 34
    },
    "normalized_at": "2026-02-03T12:48:38.480197Z",
    "effective_date": "2023-05-19",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2023-05-19",
      "bedrock_confidence": 1.0,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Eli Lilly announced plans to build a new $3.5 billion manufacturing facility for injectables and devices in Pennsylvania's Lehigh Valley. This is the fourth new US plant Lilly has unveiled as part of its 'Lilly in America' investment initiative announced last year.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "corporate_move",
        "confidence": 0.8
      },
      "extracted_date": "2023-05-19",
      "date_confidence": 1.0,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": true,
      "score": 65,
      "confidence": "medium",
      "signals_detected": {
        "strong": [],
        "medium": [
          "hybrid_company: Eli Lilly",
          "technology: injectables and devices"
        ],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": {
        "base_score": 40,
        "entity_boosts": {
          "hybrid_company": 10,
          "technology_family": 10
        },
        "recency_boost": 5,
        "confidence_penalty": 0,
        "total": 65
      },
      "reasoning": "Eli Lilly is a hybrid company involved in LAI. The item mentions injectables and devices manufacturing facility, which is a medium signal for LAI relevance. Recent date boosts the score."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 5.0,
      "bonuses": {},
      "penalties": {
        "very_old_penalty": -2.0,
        "no_entities_penalty": -2.0
      },
      "final_score": 0,
      "effective_date": "2023-05-19",
      "score_breakdown": {
        "base_score": 5.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.12,
        "total_bonus": 0,
        "total_penalty": -4.0,
        "raw_score": -3.88,
        "scoring_mode": "balanced"
      }
    }
  },
  {
    "item_id": "press_sector__fiercepharma_20260203_f18948",
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/hims-hers-uses-another-super-bowl-ad-tackle-healthcare-affordability\" hreflang=\"en\">Hims &amp; Hers uses another Super Bowl ad to tackle healthcare affordability</a>",
    "content": "The minute-long ad, which debuted online Thursday ahead of its broadcast premiere during the Feb. 8 game, starts with a stark claim: “Rich people live longer,” said by the ad’s narrator, the rapper and actor Common.",
    "url": "https://www.fiercepharma.com/marketing/hims-hers-uses-another-super-bowl-ad-tackle-healthcare-affordability",
    "published_at": "2026-02-03",
    "ingested_at": "2026-02-03T09:48:43.176623",
    "language": "en",
    "content_hash": "sha256:ee7404249a939f4bf3ee882f2e66557f876eb8f25d67f5467e515965bc8a4073",
    "metadata": {
      "author": "Andrea Park",
      "tags": [],
      "word_count": 36
    },
    "normalized_at": "2026-02-03T12:48:43.875536Z",
    "effective_date": "2023-02-02",
    "date_metadata": {
      "source": "bedrock",
      "bedrock_date": "2023-02-02",
      "bedrock_confidence": 0.9,
      "published_at": "2026-02-03"
    },
    "normalized_content": {
      "summary": "Hims & Hers, a healthcare company, aired a Super Bowl ad highlighting the issue of healthcare affordability. The ad, narrated by rapper Common, claims that rich people live longer.",
      "entities": {
        "companies": [],
        "molecules": [],
        "technologies": [],
        "trademarks": [],
        "indications": []
      },
      "event_classification": {
        "primary_type": "corporate_move",
        "confidence": 0.8
      },
      "extracted_date": "2023-02-02",
      "date_confidence": 0.9,
      "normalization_metadata": {
        "bedrock_model": "claude-3-5-sonnet",
        "canonical_version": "2.0",
        "processing_time_ms": 0
      }
    },
    "matching_results": {
      "matched_domains": [],
      "domain_relevance": {},
      "bedrock_matching_used": true
    },
    "domain_scoring": {
      "is_relevant": false,
      "score": 0,
      "confidence": "high",
      "signals_detected": {
        "strong": [],
        "medium": [],
        "weak": [],
        "exclusions": []
      },
      "score_breakdown": null,
      "reasoning": "No LAI signals detected. The item is about a healthcare company's Super Bowl ad on healthcare affordability, which is not directly relevant to the LAI domain."
    },
    "has_domain_scoring": true,
    "scoring_results": {
      "base_score": 5.0,
      "bonuses": {},
      "penalties": {
        "very_old_penalty": -2.0,
        "no_entities_penalty": -2.0
      },
      "final_score": 0,
      "effective_date": "2023-02-02",
      "score_breakdown": {
        "base_score": 5.0,
        "domain_relevance_factor": 0.05,
        "recency_factor": 0.5,
        "weighted_base": 0.12,
        "total_bonus": 0,
        "total_penalty": -4.0,
        "raw_score": -3.88,
        "scoring_mode": "balanced"
      }
    }
  }
]